These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23993328)

  • 1. Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
    Zhang D; Zhang X; Ai J; Zhai Y; Liang Z; Wang Y; Chen Y; Li C; Zhao F; Jiang H; Geng M; Luo C; Liu H
    Bioorg Med Chem; 2013 Nov; 21(21):6804-20. PubMed ID: 23993328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
    Chen D; Wang Y; Ma Y; Xiong B; Ai J; Chen Y; Geng M; Shen J
    ChemMedChem; 2012 Jun; 7(6):1057-70. PubMed ID: 22581753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
    Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
    J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors.
    Ma Y; Sun G; Chen D; Peng X; Chen YL; Su Y; Ji Y; Liang J; Wang X; Chen L; Ding J; Xiong B; Ai J; Geng M; Shen J
    J Med Chem; 2015 Mar; 58(5):2513-29. PubMed ID: 25668160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.
    Qi B; Mi B; Zhai X; Xu Z; Zhang X; Tian Z; Gong P
    Bioorg Med Chem; 2013 Sep; 21(17):5246-60. PubMed ID: 23838381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
    Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
    Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases.
    Steinig AG; Li AH; Wang J; Chen X; Dong H; Ferraro C; Jin M; Kadalbajoo M; Kleinberg A; Stolz KM; Tavares-Greco PA; Wang T; Albertella MR; Peng Y; Crew L; Kahler J; Kan J; Schulz R; Cooke A; Bittner M; Turton RW; Franklin M; Gokhale P; Landfair D; Mantis C; Workman J; Wild R; Pachter J; Epstein D; Mulvihill MJ
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4381-7. PubMed ID: 23773865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
    Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
    Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors.
    Liu TC; Peng X; Ma YC; Ji YC; Chen DQ; Zheng MY; Zhao DM; Cheng MS; Geng MY; Shen JK; Ai J; Xiong B
    Acta Pharmacol Sin; 2016 May; 37(5):698-707. PubMed ID: 27041462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization.
    An XD; Liu H; Xu ZL; Jin Y; Peng X; Yao YM; Geng M; Long YQ
    Bioorg Med Chem Lett; 2015 Feb; 25(3):708-16. PubMed ID: 25529740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
    Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOMG-833, a novel selective c-MET inhibitor, blocks c-MET-dependent neoplastic effects and exerts antitumor activity.
    Zhang HT; Wang L; Ai J; Chen Y; He CX; Ji YC; Huang M; Yang JY; Zhang A; Ding J; Geng MY
    J Pharmacol Exp Ther; 2014 Jul; 350(1):36-45. PubMed ID: 24741075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold.
    Zhao A; Gao X; Wang Y; Ai J; Wang Y; Chen Y; Geng M; Zhang A
    Bioorg Med Chem; 2011 Jul; 19(13):3906-18. PubMed ID: 21665484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
    Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases.
    Saavedra O; Claridge S; Zhan L; Raeppel F; Granger MC; Raeppel S; Mannion M; Gaudette F; Zhou N; Isakovic L; Bernstein N; Déziel R; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Wang J; Macleod AR; Besterman JM; Vaisburg A
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6836-9. PubMed ID: 19896842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
    Bladt F; Faden B; Friese-Hamim M; Knuehl C; Wilm C; Fittschen C; Grädler U; Meyring M; Dorsch D; Jaehrling F; Pehl U; Stieber F; Schadt O; Blaukat A
    Clin Cancer Res; 2013 Jun; 19(11):2941-51. PubMed ID: 23553846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.
    Bode CM; Boezio AA; Albrecht BK; Bellon SF; Berry L; Broome MA; Choquette D; Dussault I; Lewis RT; Lin MH; Rex K; Whittington DA; Yang Y; Harmange JC
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4089-93. PubMed ID: 22595176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.